U.S. markets open in 3 hours 43 minutes

Cannabics Pharmaceuticals Inc. (CNBX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1780-0.0220 (-11.00%)
At close: 3:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2000
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1700 - 0.2000
52 Week Range0.1400 - 0.6000
Volume573,759
Avg. Volume524,698
Market Cap24.769M
Beta (5Y Monthly)-0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program
    PR Newswire

    Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin and Psilocin. The announcement comes after the company was able to obtain a license from the Israeli Ministry of Health to conduct scientific research using Psylocibin and Psilocin in the company's in-house laboratory facilities in Rehovot, Israel.

  • Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33
    PR Newswire

    Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration along with a Pre-IND meeting request.

  • Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
    PR Newswire

    Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells. Study results indicate a 35% prolonged survival rate in mice exposed to RCC-33 in comparison with sham control mice, as shown by Kaplan-Meier survival curve analysis, P-value = 0.08 (Figure 1).